The observed alteration of genes encoding for key enzymes in these processes, such as PCK1 and PCK2, ALDH3A2, ALDH2, ALDH7A1, LDHB, LDHD, FADS1, FADS2, FADS5 and FASN may reprogram glucose metabolism and lipogenesis leading to AT dysmetabolism, and have profound pathophysiological effects to critically shape the tumor microenvironment. The gene discussed is FADS2; the disease is neoplasm.